Microsoft word - acop_abstract_pascalgirard.doc
Qualification of an exposure-categorical ordered multi-response population model of inolimomab
in graft-versus-host disease
Céline Dartois (1), Gilles Freyer (1,2), Mauricette Michallet (3), Emilie Hénin (1), , Isabelle Darlavoix
(4), Claudine Vermot-Desroches (4), Brigitte Tranchand (1,4), and Pascal Girard (1)*
2 Service d'Oncologie Médicale, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, France.
3 Hôpital Edouard Herriot, Hospices Civils de Lyon, France
5 Centre Anticancéreux Léon Bérard, Lyon, France.
Inolimomab, a monoclonal murine antibody directed against IL-2Rα (CD25) has shown
promising results in the treatment of steroid-resistant acute graft-versus-host disease (aGvHD). Clinical
effect is measured by categorical ordered scores quoted on different organs. The final clinical endpoint
is obtained by combining those scores into a single score as IBMTR or Glucksberg scores which are
non-ordered scores. Our purpose was to characterize the exposure-clinical endpoint of inolimomab.
Data arose from 21 patients with aGvHD (8 with IBMTR at score B, 11 at score C and 2 at
score D) following Hematopoietic Stem Cell Transplantation after a median delay of 26 days (10 – 127
days). Inolimomab was administrated at 0.1, 0.2, 0.3 or 0.4 mg/kg daily associated with
methylprednisolone (2 mg/kg) for 8 or 16 days depending of status at day 9. Then, for responder
patients, administrations were continued three times a week until day 28. Inolimomab concentrations
and PD data (aGvHD scores) were collected along the study. PD data were assessed in 4 grades
according to IBMTR and Glucksberg classification in parallel with Karnofsky scores. Population
analysis was developed using NONMEM to define the pharmacokinetic model, to test covariates, and
when apparent, to model the exposure-effect relationship by a proportional odds model . Modeling
was finally qualified by predictive check .
The best pharmacokinetic model was bi-compartmental. For each score, the most demonstrative
exposure-effect graphics linked cumulative AUC to cumulated probabilities to observe a specific score.
A categorical ordered score was fitted to each organ score. On the logit scale, the relationship was
identified as an Emax model for skin (with 2 patient subpopulations: sensitive/less sensitive) and a linear
model for intestinal tract and liver. No covariate was identified as influent on any of these parameters.
Then the model was correctly qualified by predictive check for each separate score. The final
qualification consisted in combining the separate scores into the IBMTR score, just as what is performed
by the clinicians. Once again predictive check confirmed the model.
Inolimomab exposure–effect relationships in first-line treatment of aGvHD have been
identified and modeled. The discovered dose effect relationship allows to confirm the treatment
response, then to establish the first step towards optimizing the doses of future trials.
 Zingmark PH, Kagedal M, Karlsson MO. Modelling a spontaneously reported side effect by use of
a Markov mixed-effects model. J Pharmacokinet Pharmacodyn 2005; 32(2):261-81.
 Yano Y, Beal SL, Sheiner LB. Evaluating pharmacokinetic/pharmacodynamic models using the
posterior predictive check. J Pharmacokinet Pharmacodyn 2001; 28(2):171-92.
Fármacia Botica Ouro Preto – relação das principais matérias-prima Relação das principais matérias-primas disponíveis na Farmácia Botica Ouro Preto. Na hipótese de não encontrar listada alguma substância que você procura, entre em contato que teremos o maior prazer em atendê-lo. Insumos ativos de uso interno (via oral): Ác. Acetil Salicílico Ac. Alfa lipóico Ác.
Procyanidin B-2, Extracted from Apples, Grows Hair in Clinical Trials New Health & Longevity, May 11, 2005 Subject: New Procyanidin Hair Growth Breakthrough In this special report, you will discover the all-natural botanical secret from Japan that outperforms the leading hair growth drug in laboratory tests- plus the surprising results that might just be the missing piece o